18F-FDG positron emission tomography for the assessment of histological response to neoadjuvant chemotherapy in osteosarcomas: A meta-analysis

• Published in: Surgical oncology 2012-12, Vol.21 (4), p.e165-e170
• Main Authors: Hongtao, Li, Hui, Zhao, Bingshun, Wang, Xiaojin, Wang, Zhiyu, Wang, Shuier, Zheng, Aina, He, Yuanjue, Sun, Daliu, Min, Zan, Shen, Yang, Yao
• Format: Article
• Language: English
• Subjects: 18F-FDG positron emission tomography; Bone cancer; Bone Neoplasms - diagnostic imaging; Bone Neoplasms - drug therapy; Bone Neoplasms - pathology; Chemotherapy; Fluorodeoxyglucose F18; Hematology, Oncology and Palliative Medicine; Humans; Medical imaging; Meta-analysis; Meta-Analysis as Topic; Necrosis; Neoadjuvant Therapy; Osteosarcoma - diagnostic imaging; Osteosarcoma - drug therapy; Osteosarcoma - pathology; Personal relationships; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Ratios; Response evaluation; Studies; Surgery; Tomography
• ISSN: 0960-7404; 1879-3320
• DOI: 10.1016/j.suronc.2012.07.002

Abstract Purpose The purpose of this meta-analysis was to evaluate the predicting value of fluorine-18-fluorodeoxyglucose positron emission tomography with computed tomography (18F-FDG PET-CT) in the assessment of histological response to neoadjuvant chemotherapy in patients with osteosarcomas. Methods A detailed search was made in MEDLINE, EMBASE and the Web of Knowledge for relevant original articles published in English; methodological quality of the included studies were also assessed. Two reviewers extracted data independently. Sufficient data was presented to construct a 2 × 2 contingency table. Pooled sensitivity and specificity, positive and negative likelihood ratios were estimated. A summary receiver operating characteristic curve (SROC) was constructed with the Moses' constant of linear model. A χ2 test was performed to test for heterogeneity. Results Eight studies comprising 178 patients met the inclusion criteria. The pooled sensitivity and specificity for standardized uptake values (SUV) after chemotherapy (SUV2) ≤ 2.5 were 0.734 (95% CI, 0.537–0.867) and 0.864 (95% CI, 0.510–0.975), for the ratio of standardized uptake values after (SUV2) to before (SUV1) chemotherapy SUV 2:1 ≤ 0.5 were 0.690 (95% CI, 0.497–0.833) and 0.653 (95% CI, 0.492–0.786), the positive and negative likelihood ratio (LR+/LR−) for SUV2 ≤ 2.5 were 5.397 (95% CI, 1.169–24.920) and 0.308 (95% CI, 0.165–0.577), for SUV 2:1 ≤ 0.5 were 1.989 (95% CI, 1.145–3.457) and 0.475 (95% CI, 0.247–0.915). There was no significant difference between-study heterogeneity for either LR + or LR− in any of these analyses. The area under the SROC curve for SUV2 ≤ 2.5 and SUV 2:1 ≤ 0.5 were 0.81 and 0.72, respectively. Conclusions The present meta-analysis showed that 18F-FDG PET-CT scan, as measured by the SUV before and after treatment, SUV2 ≤ 2.5 and SUV 2:1 ≤ 0.5 are valuable for predicting the histological response to chemotherapy. SUV2 ≤ 2.5 have better predicting performance than SUV 2:1 ≤ 0.5.